You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Details for Patent: 8,993,583


✉ Email this page to a colleague

« Back to Dashboard


Title:5-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)propyl]-3H-quinazolin-4-one and 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as inhibitors of human phosphatidylinositol 3-kinase delta
Abstract: Compounds that inhibit PI3K.delta. activity, including compounds that selectively inhibit PI3K.delta. activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K.delta.) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3K.delta. plays a role in leukocyte function, using the compounds also are disclosed. Exemplary compounds disclosed in this application are shown below: ##STR00001##
Inventor(s): Fowler; Kerry W. (Seattle, WA), Huang; Danwen (Bellevue, WA), Kesicki; Edward A. (Bothell, WA), Ooi; Hua Chee (Mill Creek, WA), Oliver; Amy (Bothell, WA), Ruan; Fuqiang (Bellevue, WA), Treiberg; Jennifer (Redmond, WA), Puri; Kamal Deep (Lynnwood, WA)
Assignee: ICOS Corporation (Foster City, CA)
Filing Date:Oct 08, 2013
Application Number:14/049,154
Claims:1. A pharmaceutically acceptable salt of a compound selected from the group consisting of ##STR00184## wherein the pharmaceutically acceptable salt is selected from the group consisting of hydrochloride salt, hydrobromide salt, hydroiodide salt and phosphate salt.

2. A pharmaceutical composition comprising a pharmaceutically acceptable salt of claim 1 and at least one pharmaceutically acceptable excipient.

3. The pharmaceutical composition according to claim 2, wherein the pharmaceutically acceptable salt is the hydrochloride salt.

4. The pharmaceutical composition of claim 2, wherein the compound is the S-enantiomer.

5. The pharmaceutical composition according to claim 4, wherein the pharmaceutically acceptable salt is the hydrochloride salt.

6. A kit comprising the pharmaceutically acceptable salt according to claim 1.

7. The kit according to claim 6, wherein the pharmaceutically acceptable salt is the hydrochloride salt.

8. The kit according to claim 6 wherein the compound is the S-enantiomer.

9. The kit according to claim 8, wherein the pharmaceutically acceptable salt is the hydrochloride salt.

10. The pharmaceutically acceptable salt according to claim 1, wherein the pharmaceutically acceptable salt is the hydrochloride salt.

11. The pharmaceutically acceptable salt according to claim 1, wherein the compound is the S-enantiomer.

12. The pharmaceutically acceptable salt according to claim 1, wherein the compound is ##STR00185## and the pharmaceutically acceptable salt is the hydrochloride salt.

13. The pharmaceutically acceptable salt according to claim 1, wherein the compound is ##STR00186## and the pharmaceutically acceptable salt is the hydrochloride salt.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.